"How much does short bowel syndrome treatment cost per year?"

"Annual costs vary enormously depending on treatment. Home parenteral nutrition (TPN) runs $100,000–$250,000/year. Teduglutide (Gattex) lists at $300,000–$400,000/year, though manufacturer copay assistance is widely available. Patients who can tolerate enteral nutrition pay $10,000–$30,000/year. An intestinal transplant costs $250,000–$500,000+ for surgery and the first year of care."

"Does insurance cover home TPN for short bowel syndrome?"

"Yes. Medicare Part B covers home TPN as durable medical equipment when medically necessary for intestinal failure, including SBS. Commercial plans and Medicaid also cover it. Most patients pay only their standard cost-sharing (deductible and coinsurance)."

"How many people in the US have short bowel syndrome?"

"The American Society for Gastrointestinal Endoscopy estimates 20,000–25,000 patients in the US have short bowel syndrome severe enough to require parenteral nutrition support. The most common causes are Crohn's disease with massive resection, mesenteric ischemia, and volvulus."

"What is Gattex (teduglutide) and how does it reduce TPN costs?"

"Teduglutide (brand name Gattex) is a GLP-2 analog that stimulates intestinal adaptation, allowing some SBS patients to reduce or eliminate their dependence on parenteral nutrition. Clinical trials showed roughly 60–70% of patients achieved a meaningful reduction in weekly TPN volume. Manufacturer patient assistance programs can reduce out-of-pocket costs significantly for commercially insured patients."

Short Bowel Syndrome Management Cost: TPN, Gattex, and Long-Term Care Expenses in 2025–2026

📋 Data from Medicare fee schedules & FAIR Health ✓ Reviewed by board-certified gastroenterologist 🔄 Updated May 2026

Most expensive ongoing GI therapy in American medicine. That’s not hyperbole — it’s the clinical reality of short bowel syndrome (SBS). When a patient loses enough of their small intestine to absorb nutrients independently, they depend on intravenous nutrition that can cost more than a mid-level executive salary every year. For the estimated 20,000–25,000 Americans living with SBS-related intestinal failure, according to the American Society for Gastrointestinal Endoscopy, the financial picture is as daunting as the medical one.

Understanding these costs isn’t just academic. It directly affects decisions about insurance coverage, disability applications, surgical planning, and whether to pursue newer but expensive pharmacologic treatments like teduglutide.

How SBS Develops — and Why Cost Follows Severity

Short bowel syndrome occurs when less than 200 cm of functional small intestine remains, either from surgical resection or from disease that renders the remaining bowel non-functional. The most common causes in adults are Crohn’s disease (requiring massive resection), mesenteric ischemia, and volvulus.

What you actually need — and what it costs — depends heavily on your remnant bowel anatomy:

Colon in continuity: Better fluid and carbohydrate absorption; some patients can wean off TPN
No colon (end ileostomy): High output losses; most require long-term TPN or aggressive enteral support
Length of remnant: Patients with 60–100 cm often achieve some oral autonomy; those with less than 60 cm rarely do without pharmacologic help

Annual Treatment Costs by Therapy Type

Treatment Modality	Estimated Annual Cost
Home parenteral nutrition (TPN) — full support	$100,000 – $250,000
Home TPN — partial support (2–4 days/week)	$40,000 – $100,000
Teduglutide (Gattex) injection — list price	$300,000 – $400,000
Teduglutide — after copay assistance/insurance adjustment	$0 – $15,000 OOP (varies)
Enteral nutrition / tube feeding (full)	$15,000 – $30,000
Enteral nutrition (supplemental oral)	$5,000 – $12,000
Oral rehydration solutions and supplements	$1,500 – $5,000
GI specialist and dietitian follow-up	$2,000 – $6,000
Lab monitoring (comprehensive panels, quarterly)	$2,000 – $5,000

The list price of teduglutide is striking — but it’s rarely what patients pay. Takeda’s patient assistance program (TAK-Assist) and commercial insurance copay cards typically reduce out-of-pocket costs substantially. For Medicaid patients, Gattex is covered in most states, though prior authorization requirements are stringent. The clinical argument for cost is persuasive: if Gattex eliminates or reduces TPN dependency, the net cost to the healthcare system can actually decrease.

Intestinal Transplantation: The Highest-Cost Option

For patients who can’t tolerate TPN long-term due to liver failure, recurrent line infections, or loss of venous access, intestinal transplant is the only curative option. It’s also among the most expensive procedures in all of medicine.

Intestinal Transplant Cost Component	Estimated Cost
Transplant surgery (bowel alone)	$250,000 – $350,000
Combined liver-intestine transplant	$400,000 – $600,000+
First-year post-transplant care (immunosuppression, follow-up)	$100,000 – $200,000
Annual ongoing immunosuppression + monitoring	$30,000 – $80,000
Total: first year of care	$350,000 – $800,000+

Intestinal transplant outcomes have improved significantly — one-year graft survival now exceeds 80% at experienced centers — but it remains a high-risk procedure with serious long-term complications from immunosuppression. Insurance coverage through Medicare and commercial plans is available for listed indications, but transplant centers require extensive pre-authorization.

Medicare Part B Coverage for Home TPN

Home parenteral nutrition is covered under Medicare Part B as durable medical equipment (DME), not Part A, even though it involves a nurse for line access and monitoring. This is an important distinction: Part B has a 20% coinsurance requirement after the $257 annual deductible (2025), which on a $150,000/year TPN regimen means a potential $30,000 annual exposure unless you have a Medigap supplement. Most SBS patients on lifelong TPN qualify for Medicare based on disability, not age — SSDI eligibility opens Part B coverage. A Medicare supplement plan (Medigap Plan G or Plan N) covers the 20% coinsurance and is strongly worth the premium cost for high-utilization patients like those on home TPN.

Managing the Real Out-of-Pocket Exposure

Commercial insurance (employer-sponsored):

Home TPN is typically covered under the DME benefit or the pharmacy/infusion benefit, depending on the plan structure
In-network infusion pharmacy markups matter enormously — always use a contracted home infusion company
2025 ACA OOP max: $9,450 individual / $18,900 family; most SBS patients hit this within weeks of starting TPN
Gattex copay card programs can reduce patient cost to under $15,000/year

Medicare Part B:

Covers home TPN at 80% after deductible for documented intestinal failure
Requires a physician certificate of medical necessity renewed every 90 days
Without Medigap: 20% coinsurance on $150,000–$250,000/year creates catastrophic exposure
Medigap Plan G fully covers the Part B coinsurance

Medicaid:

Home TPN covered in all states as medically necessary
Gattex covered in most states with prior authorization
Income and asset rules vary; many SBS patients qualify through disability or spend-down provisions

Applying for financial assistance:

Takeda TAK-Assist program for Gattex
NeedyMeds and RxHope for TPN supplies and formula
United Ostomy Associations of America for patients with ostomies related to SBS

Central line-associated bloodstream infections (CLABSIs) are the most dangerous and costly complication of long-term home TPN. Each CLABSI episode requires hospitalization — typically 5–10 days of IV antibiotics — at a cost of $15,000–$50,000. Over a lifetime of TPN dependence, recurrent CLABSIs can also cause progressive central venous thrombosis, eventually exhausting usable venous access sites and making TPN impossible. Strict sterile technique during line dressing changes and rigorous adherence to your home infusion team’s protocols isn’t just a medical priority — it’s a direct cost management strategy.

Disclaimer: Cost figures are estimates for US patients based on 2025–2026 published fee schedules, Medicare data, and FAIR Health benchmarks. Actual costs vary by location, provider, plan, and procedure complexity. This site does not provide medical advice. Always verify costs with your provider before scheduling.